YTHDF1 and breast carcinoma: Breast cancer cells are more susceptible to the PARP inhibitor Olaparib, adriamycin, and cisplatin when YTHDF1 is knocked down, because it facilitates S-phase entrance, DNA replication, and DNA damage repair [43].